|
BIO: James W. Wishart -- President & Chief Executive Officer, Director of Capital Genomix Inc. James Wishart is President, CEO and Director of Capital Genomix Inc., a bio-pharma company specializing in developing antibodies, cancer-biomarkers, and immunotherapy vaccines. In 2002, Mr. Wishart, founder/CEO of Odyssey Diagnostics Inc., facilitated the merger of Odyssey Diagnostics and Capital Genomix. During 1997-2001, he served as President /CEO of DYNEX Technologies, Inc., wholly-owned subsidiary of Thermo Electron Corp. ($5.4Billion, NYSE:TMO), until 2002 when Mr. Wishart acquired Dynex. Mr. Wishart led Dynex to sales of $30million. Thermo Electron (and DYNEX) develops, manufactures and markets biotechnology instruments, consumables and software for the clinical diagnostics and life sciences research markets. During his14-year tenure as senior executive with Thermo Electron, Mr. Wishart served in several capacities: 1)President/CEO of Spectra-Tech, Inc., subsidiary, Thermo Optek Corp. ($250Million, AMEX:TOC), worldwide leader in developing, manufacturing, and marketing of FTIR microscopes, accessories, and software for the analytical instrumentation market. At Spectra-Tech, Mr. Wishart conceived and implemented sales strategy that resulted in 25% increase in revenues. 2)VP-International Marketing and General Manager for Thermo Separation Products, subsidiary, Thermo Instruments Inc. ($1.3Billion company, AMEX:TIS). There he completed a $50Million acquisition and restructured company operations, with savings exceeding $750,000 annually. Mr. Wishart holds BS degree from Geneva College and has served on several Boards, including those of Thermo BioAnalysis, Ltd., DYNEX Technologies, Inc., Spectra-Tech, Inc., S.P. Japan, Inc. and Capital Genomix. | 